Fintel on MSN8h
Redburn Atlantic Upgrades Autolus Therapeutics plc - Depositary Receipt () (AUTL)
Fintel reports that on November 15, 2024, Redburn Atlantic upgraded their outlook for Autolus Therapeutics plc - Depositary Receipt () (NasdaqGS:AUTL) from Neutral to Buy. Analyst Price Forecast ...
Plus Therapeutics: Promising Growth and Stability Backed by Financial Strength and Clinical Innovations
Analyst Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Plus Therapeutics (PSTV – Research Report) and keeping the price ...
Allogene Therapeutics price target lowered to $9 from $11 at Piper Sandler
Piper Sandler analyst Biren Amin lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $11 and keeps an Overweight ...
Multiple Catalysts Ahead For Nektar Therapeutics
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?
We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...
Reuters2d
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
PTC Therapeutics' gene therapy is already approved in the European ... while European stocks rose on hopes of a better growth ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
The Motley Fool on MSN10d
Is Viking Therepautics a Buy Now?
That's a better result than we've seen from oral anti-obesity candidates in development by Roche, Lilly, Novo Nordisk, and ...